ORBIMED ADVISORS LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001055951
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2023 · 122 positions · Total reported value $4.55B · Top-10 concentration 34.1% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 60.6% · 34 new · 29 cut · 23 exited
Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking
In its Q3 2023 13F filing, ORBIMED ADVISORS LLC disclosed 122 equity positions with a combined reported value of $4.55B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 34.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2023 were SVA ($340.00M), BSX ($174.60M), HUM ($166.63M). By sector, the heaviest allocations are Health Care 69.1%, Consumer Discretionary 1.8%.
Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions.
The largest new positions opened in Q3 2023 were SVA ($340.00M), BSX ($174.60M), HUM ($166.63M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2023)
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-10 | Buy | Electra Therapeutics, Inc. | 2,000 | $8.45 | SEC filing |
| 2026-11-10 | Buy | Electra Therapeutics, Inc. | 20,700 | $8.45 | SEC filing |
| 2026-11-09 | Buy | Electra Therapeutics, Inc. | 16,000 | $8.24 | SEC filing |
| 2026-11-09 | Buy | Electra Therapeutics, Inc. | 4,000 | $8.24 | SEC filing |
| 2026-11-06 | Buy | Electra Therapeutics, Inc. | 39,600 | $7.85 | SEC filing |
| 2026-11-06 | Buy | Electra Therapeutics, Inc. | 9,816 | $7.85 | SEC filing |
| 2026-11-05 | Buy | Electra Therapeutics, Inc. | 125,200 | $7.31 | SEC filing |
| 2026-11-05 | Buy | Electra Therapeutics, Inc. | 30,891 | $7.31 | SEC filing |
Fund Profile
ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.
Investment Approach
ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.
Asset Classes
ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.
Key People
Samuel Isen - Co-founder and Managing Partner
Steven Bloom - Co-founder and Managing Partner
The firm also has several other managing partners and investment professionals
Notable Facts
ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.
This information is based on public disclosures; investment decisions should reference official filings.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
2.72M | $340.00M | 7.48% | New | |
| 2 |
|
3.31M | $174.60M | 3.84% | New | |
| 3 |
|
342.50K | $166.63M | 3.67% | New | |
| 4 |
|
499.00K | $145.85M | 3.21% | New | |
| 5 |
|
556.80K | $143.10M | 3.15% | New | |
| 6 |
|
1.62M | $142.91M | 3.14% | New | |
| 7 |
|
9.00M | $122.92M | 2.70% | New | |
| 8 |
|
1.05M | $108.61M | 2.39% | New | |
| 9 |
|
2.27M | $106.63M | 2.35% | New | |
| 10 |
|
186.00K | $99.91M | 2.20% | New | |
| 11 |
|
2.17M | $98.41M | 2.17% | New | |
| 12 |
|
3.97M | $91.75M | 2.02% | New | |
| 13 |
|
401.90K | $90.78M | 2.00% | New | |
| 14 |
|
2.90M | $86.13M | 1.90% | New | |
| 15 |
|
2.24M | $84.53M | 1.86% | New | |
| 16 |
|
14.57M | $83.47M | 1.84% | New | |
| 17 |
|
1.22M | $80.68M | 1.77% | New | |
| 18 |
|
73.11M | $80.43M | 1.77% | New | |
| 19 |
|
2.90M | $78.85M | 1.74% | New | |
| 20 |
|
269.00K | $73.51M | 1.62% | New | |
| 21 |
|
143.80K | $72.79M | 1.60% | New | |
| 22 |
|
17.99M | $67.39M | 1.48% | New | |
| 23 |
|
231.50K | $66.23M | 1.46% | New | |
| 24 |
|
529.20K | $64.15M | 1.41% | New | |
| 25 |
|
3.78M | $61.58M | 1.35% | New | |
| 26 |
|
2.62M | $58.23M | 1.28% | New | |
| 27 |
|
165.40K | $57.52M | 1.26% | New | |
| 28 |
|
5.33M | $54.17M | 1.19% | New | |
| 29 |
|
3.44M | $51.86M | 1.14% | New | |
| 30 |
|
1.01M | $51.34M | 1.13% | New | |
| 31 |
|
330.00K | $49.19M | 1.08% | New | |
| 32 |
|
2.29M | $48.69M | 1.07% | New | |
| 33 |
|
1.51M | $48.29M | 1.06% | New | |
| 34 |
|
17.71M | $47.65M | 1.05% | New | |
| 35 |
|
415.90K | $46.79M | 1.03% | New | |
| 36 |
|
4.08M | $46.73M | 1.03% | New | |
| 37 |
|
12.05M | $45.13M | 0.99% | New | |
| 38 |
|
22.36M | $44.05M | 0.97% | New | |
| 39 |
|
920.58K | $40.74M | 0.90% | New | |
| 40 |
|
6.56M | $40.30M | 0.89% | New | |
| 41 |
|
3.32M | $40.14M | 0.88% | New | |
| 42 |
|
5.56M | $39.58M | 0.87% | New | |
| 43 |
|
4.01M | $39.04M | 0.86% | New | |
| 44 |
|
7.62M | $38.32M | 0.84% | New | |
| 45 |
|
253.31K | $36.99M | 0.81% | New | |
| 46 |
|
5.78M | $36.93M | 0.81% | New | |
| 47 |
|
70.00K | $35.29M | 0.78% | New | |
| 48 |
|
9.24M | $34.93M | 0.77% | New | |
| 49 |
|
127.30K | $34.21M | 0.75% | New | |
| 50 |
|
10.91M | $33.71M | 0.74% | New | |
FAQ
What did ORBIMED ADVISORS LLC buy in 2023-Q3?
In its 2023-Q3 13F filing, ORBIMED ADVISORS LLC reported 122 equity positions worth $4.55B in aggregate; its largest disclosed positions were SVA ($340.00M), BSX ($174.60M), HUM ($166.63M).
How large is ORBIMED ADVISORS LLC's portfolio?
ORBIMED ADVISORS LLC reported $4.55B of long equity holdings across 122 positions as of 2023-Q3. Top-10 holdings account for 34.1% of reported value.
What is ORBIMED ADVISORS LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.